Results 161 to 170 of about 1,113 (191)

Wirksamkeit und Sicherheitsprofil von Iluvien ® im klinischen Alltag

2016
Hintergrund: Iluvien® (Fluocinolon Acetonide) ist als second line Therapie seit 2013 bei chronischem DMÖ, das auf andere verfügbare Therapien unzureichend anspricht, zugelassen. Methoden: Retrospektive Fallserie aller seit 2013 in unserer Klinik mit Iluvien® behandelten Augen [zum vollständigen Text gelangen Sie über die oben angegebene URL]
Bendschneider, D, Wachtlin, J
openaire   +2 more sources

Fluocinolone acetonide (Iluvien) extended-release intravitreal implant for diabetic macular edema

Expert Review of Ophthalmology, 2014
Fluocinolone acetonide (FAc) is a corticosteroid used in the FAc implant, a novel drug-delivery device currently approved in Europe but not yet approved in the USA. The drug delivery system for FAc implant allows a sustained delivery in a more posterior location in the eye and can be delivered in an outpatient setting.
Michelle V Carle, Thomas G Chu, David S Boyer   +2 more
openaire   +1 more source

Iluvien monotherapy for diabetic macular oedema in vitrectomised and non‐vitrectomised eyes: one year data

Acta Ophthalmologica, 2016
PurposeTo assess the effectiveness of the Fluocinolone intravitreal implant (Iluvien) in patients with diabetic macular oedema (DMO) following previous pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). The data from vitrectomised eyes are compared with a consecutive group of non‐vitrectomised eyes with DMO who received the ...
A. Hawrami, H. Laviers, S. Patra, H. Zambarakji   +3 more
openaire   +1 more source

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the treatment of ocular juvenile xanthogranuloma

Archivos de la Sociedad Española de Oftalmología (English Edition)
This is the case of a 14-years-old woman referred to our ophthalmology department with suspected iris juvenile xanthogranuloma, with reported bilateral, hematic recurrent uveitis as soon as she discontinued treatment with topical prednisolone acetate eye drops.
M, Larrañaga Cores, M, Asencio Durán, J, Peralta Calvo, M, Feito Rodríguez, G, Amorena Santesteban, A, Del Hierro Zarzuelo, A, Boto-de-Los-Bueis   +6 more
openaire   +2 more sources

Erste Erfahrungen mit Fluocinolonacetonid (Iluvien) in der Behandlung des diabetischen Makulaödems (K)

2015
28.
Hornischer, C, Jochmann, C, Wiedemann, P
openaire   +2 more sources

Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema

Drugs, 2017
Fluocinolone acetonide intravitreal implant 0.19 mg (ILUVIEN®) is a nonbiodegradable, injectable, corticosteroid implant that is approved in several countries, including the USA, for the treatment of diabetic macular edema (DME). ILUVIEN® releases fluocinolone acetonide at an initial rate of 0.25 µg/day (average rate 0.2 µg/day) and lasts 36 months. In
openaire   +2 more sources

[Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].

Journal francais d'ophtalmologie, 2016
Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a ...
G, Soubrane, F, Behar-Cohen
openaire   +1 more source

Treatment of Iluvien® malposition with YAG laser: A case study approach

Journal Français d'Ophtalmologie, 2023
M, Rustullet-Olivé, R, Fernández-Hernández, D, Vilaplana-Blanch   +2 more
openaire   +2 more sources

Un OFNI, ou « Objet flottant nommé Iluvien », dans l’œil

Journal Français d'Ophtalmologie, 2022
Y. Ghaffour, F. Varenne, V. Soler
openaire   +1 more source

Intraocular Suture of a Migrated ILUVIEN Implant into the Vitreous Cavity

Ophthalmology Retina, 2020
Felix Rommel, Mahdy Ranjbar, Salvatore Grisanti   +2 more
openaire   +2 more sources